These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 17720725

  • 1. Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis.
    Gengenbacher M, Sebald HJ, Villiger PM, Hofstetter W, Seitz M.
    Ann Rheum Dis; 2008 May; 67(5):620-4. PubMed ID: 17720725
    [Abstract] [Full Text] [Related]

  • 2. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.
    Woo JH, Lee HJ, Sung IH, Kim TH.
    J Rheumatol; 2007 Aug; 34(8):1753-9. PubMed ID: 17610317
    [Abstract] [Full Text] [Related]

  • 3. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T, Jouen F, Brazier M, Clayssens S, Klemmer N, Ménard JF, Mejjad O, Daragon A, Tron F, Le Loët X, Vittecoq O.
    Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
    [Abstract] [Full Text] [Related]

  • 4. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
    Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T.
    Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
    [Abstract] [Full Text] [Related]

  • 5. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
    Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, Mendelson E, Wigler I, Caspi D, Paran D.
    Semin Arthritis Rheum; 2010 Jun; 39(6):442-7. PubMed ID: 19246078
    [Abstract] [Full Text] [Related]

  • 6. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
    Heiberg MS, Nordvåg BY, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK.
    Arthritis Rheum; 2005 Aug; 52(8):2506-12. PubMed ID: 16052584
    [Abstract] [Full Text] [Related]

  • 7. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis.
    Kiortsis DN, Mavridis AK, Filippatos TD, Vasakos S, Nikas SN, Drosos AA.
    J Rheumatol; 2006 May; 33(5):921-3. PubMed ID: 16541480
    [Abstract] [Full Text] [Related]

  • 8. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis.
    Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA.
    Ann Rheum Dis; 2005 May; 64(5):765-6. PubMed ID: 15458960
    [Abstract] [Full Text] [Related]

  • 9. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.
    Lange U, Teichmann J, Müller-Ladner U, Strunk J.
    Rheumatology (Oxford); 2005 Dec; 44(12):1546-8. PubMed ID: 16263785
    [Abstract] [Full Text] [Related]

  • 10. The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis.
    Torikai E, Kageyama Y, Takahashi M, Suzuki M, Ichikawa T, Nagafusa T, Nagano A.
    Rheumatology (Oxford); 2006 Jun; 45(6):761-4. PubMed ID: 16436492
    [Abstract] [Full Text] [Related]

  • 11. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N, Kawauchi S, Furuya T, Inaba N, Matsuda K, Ando S, Ogasawara M, Aburatani H, Kameda H, Amano K, Abe T, Ito S, Takeuchi T.
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [Abstract] [Full Text] [Related]

  • 12. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab.
    Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S, Bizaki A, Kritikos H, Boumpas DT.
    J Rheumatol; 2006 Dec; 33(12):2440-6. PubMed ID: 17014005
    [Abstract] [Full Text] [Related]

  • 13. Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.
    Familian A, Voskuyl AE, van Mierlo GJ, Heijst HA, Twisk JW, Dijkmans BA, Hack CE.
    Ann Rheum Dis; 2005 Jul; 64(7):1003-8. PubMed ID: 15958758
    [Abstract] [Full Text] [Related]

  • 14. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.
    De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F.
    Arthritis Rheum; 2003 Apr; 48(4):1015-23. PubMed ID: 12687543
    [Abstract] [Full Text] [Related]

  • 15. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis.
    Seriolo B, Paolino S, Sulli A, Ferretti V, Cutolo M.
    Ann N Y Acad Sci; 2006 Jun; 1069():420-7. PubMed ID: 16855169
    [Abstract] [Full Text] [Related]

  • 16. The tumor necrosis factor-{alpha}-blocking agent infliximab inhibits interleukin 1beta (IL-1beta) and IL-6 gene expression in human osteoblastic cells.
    Musacchio E, Valvason C, Botsios C, Ostuni F, Furlan A, Ramonda R, Modesti V, Sartori L, Punzi L.
    J Rheumatol; 2009 Aug; 36(8):1575-9. PubMed ID: 19567627
    [Abstract] [Full Text] [Related]

  • 17. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
    Park MC, Chung SJ, Park YB, Lee SK.
    Scand J Rheumatol; 2008 Aug; 37(3):173-8. PubMed ID: 18465450
    [Abstract] [Full Text] [Related]

  • 18. Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response.
    Pachot A, Arnaud B, Marrote H, Cazalis MA, Diasparra J, Gouraud A, Mougin B, Miossec P.
    J Rheumatol; 2007 Nov; 34(11):2158-61. PubMed ID: 17896807
    [Abstract] [Full Text] [Related]

  • 19. LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis.
    Edwards JR, Sun SG, Locklin R, Shipman CM, Adamopoulos IE, Athanasou NA, Sabokbar A.
    Arthritis Rheum; 2006 May; 54(5):1451-62. PubMed ID: 16649193
    [Abstract] [Full Text] [Related]

  • 20. Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis.
    Choi ST, Kim JH, Kang EJ, Lee SW, Park MC, Park YB, Lee SK.
    Rheumatology (Oxford); 2008 Dec; 47(12):1775-9. PubMed ID: 18854347
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.